Should a Second Transurethral Resection Be Performed in All Patients with T1 or High-Grade Non-Muscle-Invasive Bladder Cancer?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F11%3A7069" target="_blank" >RIV/00064203:_____/11:7069 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/11:7069

Výsledek na webu

<a href="http://www.sciencedirect.com/science/article/pii/S1569905611000297" target="_blank" >http://www.sciencedirect.com/science/article/pii/S1569905611000297</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Should a Second Transurethral Resection Be Performed in All Patients with T1 or High-Grade Non-Muscle-Invasive Bladder Cancer?

Popis výsledku v původním jazyce

Context: Transurethral resection (TUR) is a critical step in the management of non-muscle-invasive bladder cancer (NMIBC). Because of the high risk of tumour persistence and understaging, the routine second TUR performed after 2-6 wk is recommended by European Association of Urology guidelines in all patients with T1 or high-grade NMIBC. Objective: To summarise arguments that support the recommendation of routine second TUR in all patients with T1 or high-grade NMIBC. Evidence acquisition: Data and arguments were retrieved from a critically selected list of articles and abstracts dealing with the surgical treatment of NMIBC. Evidence synthesis: In patients with T1 tumours, the risk of tumour persistence and tumour understaging detected by the second TUR was 33-78% and 2-28%, respectively. The pathologic finding achieved by second TUR can modify the treatment strategy in a significant number of patients. Correct staging in NMIBC enables the selection of the optimal treatment modality an

Název v anglickém jazyce

Should a Second Transurethral Resection Be Performed in All Patients with T1 or High-Grade Non-Muscle-Invasive Bladder Cancer?

Popis výsledku anglicky

Context: Transurethral resection (TUR) is a critical step in the management of non-muscle-invasive bladder cancer (NMIBC). Because of the high risk of tumour persistence and understaging, the routine second TUR performed after 2-6 wk is recommended by European Association of Urology guidelines in all patients with T1 or high-grade NMIBC. Objective: To summarise arguments that support the recommendation of routine second TUR in all patients with T1 or high-grade NMIBC. Evidence acquisition: Data and arguments were retrieved from a critically selected list of articles and abstracts dealing with the surgical treatment of NMIBC. Evidence synthesis: In patients with T1 tumours, the risk of tumour persistence and tumour understaging detected by the second TUR was 33-78% and 2-28%, respectively. The pathologic finding achieved by second TUR can modify the treatment strategy in a significant number of patients. Correct staging in NMIBC enables the selection of the optimal treatment modality an

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Urology Supplements

ISSN

1569-9056

e-ISSN

—

Svazek periodika

10

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

4

Strana od-do

"E8"-"E11"

Kód UT WoS článku

000290726700003

EID výsledku v databázi Scopus

—